Thus, whilst the CVOTs provide valuable and supportive evidence of a benefit of GLP-1 RAs on HF in people with type 2 diabetes, additional trials are required to fully understand the magnitude and nature of such a potential effect, including if it applies to both prevention and treatment of the condition. This evidence concerns the gene GCG and type 2 diabetes mellitus.